Lexeo Therapeutics price target raised to $20 from $9 at Leerink

Leerink analyst Mani Foroohar raised the firm’s price target on Lexeo Therapeutics (LXEO) to $20 from $9 and keeps an Outperform rating on the shares. The firm notes the company announced a regulatory update and presented additional data for LX2006 in Friedreich’s ataxia cardiomyopathy. Based on a meeting with CBER personnel, FDA is open to pooling data from the ongoing Phase 1/2 SUNRISE-FA and pivotal studies, and assessing left ventricular mass index at an earlier timepoint. Leerink views this update as positive on regulatory flexibility and a relatively straightforward path to approval. While FDA openness to a pooled dataset and earlier evaluation of LVMI accelerates timelines, the need to submit CMC comparability data nudges pivotal initiation from early-26 to the first half of 2026. Additional clinical data further de-risks LX2006’s with dose-dependent, durable LVMI reduction, clean safety and improvements in mFARS representing potential upside to the firm’s/Street TAM estimates.